Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. (the "Company") filed this Form 8-K on May 15, 2017, reporting events occurring on May 17 and May 18, 2017. The Company is a Nevada corporation focused on medical technology. The filing details a material definitive agreement involving the acquisition of a patent by a wholly-owned subsidiary and the establishment of a Rule 10b5-1 trading plan by the parent company.
Key Financial Metrics and Agreements
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins for a specific period. Instead, it outlines the financial terms of a new asset acquisition and a potential equity sale plan:
- Patent Acquisition Cost: $100,000 initial payment due by June 29, 2017.
- Royalty Obligations: 5% of gross sales from products derived from the patent for five years; 50% of sale price or ongoing payments from third-party licenses.
- Maximum Liability Cap: Aggregate royalty payments are capped at $2,500,000.
- 10b5-1 Plan: Parent company CMH plans to sell up to 750,000 shares of common stock subject to minimum price thresholds, with trading commencing no sooner than May 30, 2017.
Material Changes and Milestone Payments
The filing discloses a material change in the Company's intellectual property portfolio and potential future cash outflows contingent on clinical trial progress. StemSpine, LLC, a subsidiary, acquired U.S. Patent No. 9,598,673 covering stem cell treatments for lower back pain. Future payments are tied to specific development milestones:
- Autologous Cell Path: $100,000 upon signing a university agreement for an IRB clinical trial; $200,000 upon trial completion.
- Allogenic Cell Path: $100,000 upon FDA IND filing; $200,000 upon Phase 1-2 first patient dosing; $400,000 upon Phase 3 first patient dosing.
- Payment Method: Except for the initial $100,000, milestone payments may be made in cash or Company common stock at a 30% discount to the market price.
Guidance, Risks, and Contingencies
The Company issued a press release on May 18, 2017, containing forward-looking statements regarding the patent's potential. Management explicitly states that actual results may differ materially due to factors discussed in the 2016 Form 10-K. The filing notes that the Company assumes no obligation to update these statements. A significant contingency exists regarding the payment method for milestones, which could result in significant dilution if paid in stock at a 30% discount. Additionally, the 10b5-1 plan introduces potential downward pressure on the stock price depending on market conditions and the execution of the 750,000 share sale.
Investor Verification Checklist
- Verify the current cash position of StemSpine, LLC to assess the ability to meet the $100,000 payment due June 29, 2017.
- Review the Company's 2016 Form 10-K for specific risk factors related to clinical trials and stem cell technology.
- Monitor upcoming Form 4 or Form 144 filings to track the execution of the 10b5-1 plan by CMH.
- Confirm the status of the patent (U.S. Patent No. 9,598,673) and the qualifications of the inventors (Thomas Ichim, Amit Patel, Annette Marleau) who are also Company directors/officers.
- Assess the potential dilution impact if milestone payments are settled in stock at the specified 30% discount.